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ABSTRACT 
 
Background:  Baseline prognostic biomarkers stratifying treatment strategies in first-
line metastatic colorectal cancer (mCRC) are lacking. Angiopoietin-2 (Ang-2) is 
proposed as a potential biomarker in several cancers. We therefore decided to 
establish the additional prognostic value of Ang-2 for overall survival (OS) in first-line 
mCRC patients. 
Methods: We enrolled 177 patients treated with a bevacizumab containing 
chemotherapy in two prospective phase II clinical trials. Patient plasma samples were 
collected at baseline. Enzyme-linked immunosorbent assays were used to measure 
Ang-2. 
Results: The multivariable Cox model identified increased LDH (HR=1.60, 95%CI: 
1.04-2.45, p=0.03) and Ang-2 log-transformation level (HR=1.59, 95%CI: 1.14-2.21, 
p=0.0065) as two significant independent OS prognostic factors. It exhibited good 
calibration (p=0.8) and discrimination (C-index: 0.64; 95%CI: 0.58-0.68). 
Ang-2 parameter inclusion in the GERCOR reference model significantly and strongly 
improved its discriminative ability since the C-statistic increased significantly from 
0.61 to 0.63 (bootstrap mean difference=0.07, 95%CI: 0.069-0.077). Interestingly, the 
addition of Ang-2 binary information with a 5 ng/mL cut-off value to the GERCOR 
model allowed the reclassification of intermediate-risk profile patients (41%) into two 
subsets of low and high-risks. 
Conclusions: Our study provides robust evidence in favour of baseline Ang-2 
prognostic value for OS adding to the conventional factors. Its assessment appears 
to be useful for the improvement in risk stratification for patients with intermediate-
risk profile. 
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Impact: Ang-2 ability to predict OS at diagnosis could be of interest in the selection 
of patients eligible to intermittent or sequential therapeutic strategies dedicated to the 
optimization of patient's quality of life and chemotherapy cost-effectiveness. 
 5
INTRODUCTION 
 
Remarkable improvement of colorectal cancer patient’s survival was reported in last 
years, mainly due to the increasing indications of metastatic surgery and the 
availability of a growing number of chemotherapies and biotherapies during the 
course of the disease.(1) Several medical options are currently available to treat 
metastatic colorectal cancer patients (mCRC) in the first-line setting ranging from 
chemotherapy intensification using FOLFOXIRI±biotherapies (2-3) and step-up 
strategies based on a first prescription of 5-Fluorouracile (5FU) 
monotherapy±bevacizumab.(4-7) Therefore, the identification of biomarkers at 
diagnosis contributing to the prediction of individual mCRC patient’s prognosis will be 
a critical step to better individualize and stratify mCRC treatments. 
Formation of new blood vessels is a major process allowing cancer 
progression and tumor spread. Several evidence showed that angiogenic molecular 
regulation is linked to the multistep oncogenesis leading to activation of an increasing 
number of angiogenic-related growth factors during the course of the disease.(8) The 
impact of bevacizumab, a Vascular Endothelial Growth Factor neutralizing 
monoclonal antibody (anti-VEGFA), on mCRC patient’s survival, confirmed the role of 
VEGF-dependent neoangiogenesis in this disease. In addition, the bevacizumab 
lower efficacy in advanced disease (beyond the second line of therapy) pointed out 
that the regulation of advanced mCRC angiogenesis might involve other angiogenic 
growth factors.  
Several investigations were performed to determine the role of cancer-related 
angiogenesis in mCRC prognosis. Over the last decade, many seric potential 
prognostic factors were investigated in mCRC patients without any positive 
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association with OS at baseline.(9-10)  
The presence of alternative angiogenesis pathways promoting cancer 
progression was firstly suggested by the lack of efficacy of VEGF blockade in some 
tumor models in mice.(11) Further studies demonstrated that Angiopoietin-2 (Ang-2), 
a ligand of Tie2 receptor (12) was able to induce an anarchical blood vessel 
organization during cancer progression.(13-14) Preclinical studies confirmed that 
VEGFR and Tie2 signalling were two independent mechanisms promoting tumor 
angiogenesis and cancer progression.(15) Moreover, VEGF and Ang-2 were 
independent biomarkers at baseline to predict survival in advanced hepatocarcinoma 
patients treated by sorafenib in the SHARP study.(16) 
In first-line mCRC, Goede V. and colleagues proposed Ang-2 as a possible 
prognostic biomarker for OS at diagnosis, based on a pioneering study performed in 
34 patients treated with bevacizumab and chemotherapy.(17) In a cohort of 51 
mCRC patients treated by FOLFIRI-3 and bevacizumab we have also recently 
observed an association between baseline Ang-2 plasmatic levels, OS and PFS.(18) 
Other exploratory studies pointed out its potential prognostic value by the description 
of an association between Ang-2 and OS or PFS, in small cohorts of patients.(19-20) 
However, the independent and additional Ang-2 prognostic value for OS, among the 
conventional prognostic factors and prognostic scores used in clinical practice is not 
yet established. 
Some prognostic scores have been proposed in mCRC patients, based on 
clinical, biological and radiological parameters. The Clinical Risk Score of Fong (from 
Memorial Sloan Kettering Cancer Center), or the Nordlinger score (21-22) are used 
in daily practice to determine the prognosis of mCRC patients candidate for 
metastatic surgery. Another score usually chosen is the Kohne score, based on the 
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Performance Status (PS), white blood cell count (WBC), number of metastatic sites, 
and Alkaline Phosphatase level.(23) More recently, the simplified score of the 
Groupe Coopérateur Multidisciplinaire en Oncologie GERCOR offered a convenient 
fashion to investigate mCRC patient’s prognosis, by monitoring PS and LDH status 
and exhibited a better discrimination ability.(24) Using these two parameters, the 
GERCOR score could identify three distinct groups of mCRC patients according to 
their risk of death: a low-risk group (median OS= 29.8 months), an intermediate-risk 
group (median OS= 19.5 months), and a high-risk group (median OS=13.9 months). 
Kohne and GERCOR scores are mainly used to estimate the prognosis of 
unresectable mCRC. To date, such scores are necessary tools in unresectable 
mCRC for the management of aggressiveness of the treatment’s strategy, its 
personalization, and the design optimization for future clinical trials. Nowadays, 
staging systems still remain rare and have to be improved.  
Consequently, we decided to perform a validation study to assess the 
prognostic value of Ang-2 in mCRC. For this purpose, Ang-2 plasmatic levels were 
monitored in 177 mCRC patients enrolled in two prospective clinical trials, to confirm 
the potential prognostic value of Ang-2 as a biomarker of interest for the prediction of 
OS. We also investigate the added value of Ang-2 at baseline among conventional 
parameters. 
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MATERIALS AND METHODS 
 
Population 
Individual patient data were collected from two previous prospective cohorts, both 
containing bevacizumab treatment in first-line mCRC patients. 
The "cohort set-1", was a pilot, single-arm, multicenter, phase II trial 
conducted to characterize the response rate and toxicity profile of a FOLFIRI-
3/bevacizumab association as initial treatment for mCRC. Sixty-one patients were 
enrolled between october 2007 and october 2009, and levels of plasma Ang-2 were 
measured in 51 patients by enzyme-linked immunosorbent assay at baseline. Tumor 
responses were assessed every eight weeks by spiral-computed tomography until 
progression. As the main objective was to assess the tumor response rate, surgery of 
metastases was allowed after 6 cycles of treatment, and the precise timing left at 
discretion of investigators.(18) This phase II study was funded by the university 
hospital of Besançon, and registered on ClinicalTrials.gov (study NCT00544011, 
approved by french ethical committee in 2007, February 1st). 
The "cohort set-2" was conducted from 2007 to 2010 to evaluate the role of 
contrast-enhanced ultrasound with gas-encapsulated microbubbles, to assess anti-
angiogenic efficacy of bevacizumab in first-line metastatic colorectal cancers with 
unresectable liver mCRC metastases.(25) Of note, all patients had unresectable liver 
metastases. Tumor responses were assessed every twelve weeks or less until 
progression. This study was funded by the French National Institute of Cancer and 
registered on ClinicalTrials.gov (study NCT00489697, approved by french ethical 
committee in 2006, November 11th). 
In both studies all patients gave written informed consent, and were followed 
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until death.Data were anonymized. Population selection during the study is 
summarized in the flow chart (Figure 1). 
 
Data extraction: 
The following data were collected for each patient in the two cohorts: center and 
patient identification, age, sex, performance status, primary tumor site (colon, 
rectum), site of metastases (liver-limited, liver and other, other), time of metastasis 
diagnostic (synchronous, metachronous), primary tumor resection, LDH level at 
baseline (normal value was considered if LDH were below 350 UI/L), lymphocyte and 
leucocyte counts, survival status, and date of last news or death. Of note, ALP level 
was not available in "cohort set-2". 
Ang-2 plasma sample measurement procedure is precisely described in 
supplementary materials (Supp methods). 
 
Statistical analysis 
We provided the mean (SD) values and frequency (percentages) for the description 
of continuous and categorical variables, respectively. The means and the proportion 
were compared using Student’s t test and the chi-squared test (or Fisher’s exact test, 
if appropriate), respectively. Due to the skewed Angiopoietin-2 distribution we used 
for its description the median, and the interquartile range for the dispersion 
measurement, as recommended.(26) Wilcoxon rank-sum test was performed for 
Ang-2 distribution comparison among the cohort set. 
OS was calculated from the date of study enrolment to the date of death from 
any cause. Alive patients were censored at the last follow-up. OS was estimated 
using Kaplan Meier method and described using median or rate at specific time 
 10
points with 95%CI. Follow-up was calculated using reverse Kaplan-Meier 
estimation.(27) A Cox proportional hazard model was performed to estimate the 
hazard ratio (HR) and 95% confidence intervals for the factors associated with OS. 
The association of parameters at enrolment with OS was first assessed using 
univariate Cox analysis and then included (for those with p<0.05) in a final 
multivariate Cox regression model with stepwise backward elimination. When used in 
continuous in the Cox modelisation, Ang-2 variable had to be normalized by 
logarithmic transformation, considering its skewed distribution. Hazard proportionality 
was checked by plotting log-minus-log survival curves. 
Accuracy of the model was checked regarding two parameters: discrimination 
and calibration.(28) The predictive value and the discrimination ability of the model 
was evaluated with Harrell’s Concordance (C)-index. One thousand random samples 
of the population were used to derive 95%CI for the Harrell’s Concordance statistic. 
Calibration and goodness of fit of the model were assessed by using the extension of 
Hosmer-Lemeshow test for survival analysis and p-value greater than 0.1 was 
considered as an indicator for acceptable agreement.  
Internal validity of the model was assessed by a bootstrap sample procedure. 
Several approaches have been proposed to assess the performance in samples of 
the same population (internal validation).(29)  
Sensitivity analyses were performed for univariate and multivariate Cox 
models with a stratified approach on the cohort set parameter that allowed to 
consider the two cohort heterogeneities in the Cox modelisation. 
We further focused on the improvement of one reference prognostic model for 
OS (GERCOR model) performance after the inclusion of Ang-2 measurement, 
comparing two sets of predictions for death: one based on a Cox proportional hazard 
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model without Ang-2 parameter and one based on a model with Ang-2 parameter. 
The discrimination ability and incremental value of Ang-2 level to the GERCOR score 
was evaluated with the use of C statistic. This analysis was repeated 1,000 times 
using bootstrap samples to derive 95%CIs for the difference in the C statistic 
between models. We also used net continuous reclassification improvement (NRI) 
and integrated discrimination improvement (IDI) to quantify the performance and the 
net benefit of the addition of Ang-2 to the reference model for the prediction of 48 
months death probability.(30-32) Continuous NRI has several limitations but would 
give a consistent message and is therefore a descriptive marker.(33) Of note, cNRI 
does not consider the magnitude of the change, but only the direction. This is done 
by the IDI. When significantly greater than 0, IDI and cNRI are in favor of a net 
benefit of the addition of the marker of interest to the reference model considered. 
We finally investigated the possibility to provide a simple implementation of 
Ang-2 monitoring in clinical practice with the determination of a cut-off value by 
contrasting Ang-2 level distributions in boxplot among healthy volunteers and mCRC 
patients. 
The analyses were conducted using SAS 9.2 (Statistical Analysis System, 
Cary, NC, USA) and R 3.0.2 (R foundation for Statistical Computing). All statistical 
tests were 2-sided, and probability values <0.05 were regarded as significant. 
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RESULTS 
 
Population: 
The characteristics of the 177 eligible patients are summarized in table 1. Fifty-one 
samples were available from "cohort set-1", and 126 from “cohort set-2”. Patient’s 
characteristics of these two cohorts are similar, except for sex and liver metastatic 
involvement. Ang-2 values were also different in the two cohorts. Of note, the 
statistical unbalance in metastatic sites between the two cohorts was awaited since 
liver metastasis was an inclusion criteria in the “cohort set-2”. The rate of PS 2 was 
2% in the “cohort set-1”, instead of 5% in the “cohort set-2”, we consequently 
differentiated the patients PS 0 from the patients PS > 0. There were 23 (45%), and 
45 (36%) patients with liver exclusive metastatic sites. Surgery of the primary tumor 
was performed in 28 (57%) and 82 (65%) patients, in the cohorts set-1 and set-2, 
respectively. LDH values at baseline were available in 33 and 82 patients and 
increased upper limit normal values in 13 (39%) and 46 (56%) patients of cohort set-
1 and set-2, respectively. 
 
Ang-2 plasma level biomarker and prediction of OS 
The association of clinical, biological, and radiological parameters with risk of death 
in univariate and multivariate Cox regression analysis with stepwise backward 
elimination was performed and results are shown in table 2. We identified six 
variables as prognostic factors for OS in the univariate analysis: Ang-2 log-value 
(HR=1.91; 95%CI: 1.492; 2.448; p< 0.0001), metastatic localisations (liver and other: 
HR=1.82; 95%CI: 1.305-2.527 - other: HR=0.69; 95%CI: 0.326-1.442; p=0.0003 - 
liver alone as the reference), absence of resection of the primary site (HR=1.43 
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95%CI: 1.035-1.984; p=0.0304), synchronous metastases (HR=1.46; 95%CI: 1.035-
2.054; p=0.0308), high LDH level (HR=2.03; 95%CI: 1.373-2.988; p=0.0004) and 
leucocyte count (HR=1.12; 95%CI: 1.056-1.188; p=0.0002) (table 2). 
Two independent predictors of OS were identified by the multivariate analysis: 
LDH high level (HR=1.60; 95%CI: 1.04-2.45; p=0.03) and log Ang-2 high level 
(HR=1.59; 95%CI: 1.14-2.21; p=0.0065) (table 2). 
 
Final Multivariate model performance assessment 
Accuracy of the model was checked regarding two parameters: discrimination and 
calibration, which measure the ability to separate patients with different prognosis 
and to provide unbiased survival predictions in groups of similar patients, 
respectively. 
Our final multivariable Cox model exhibited good calibration (Hosmer–
Lemeshow with deciles p=0.8) and acceptable discrimination (C-statistic 0.64; 
95%CI: 0.58-0.68). 
 
Internal validation of the final model  
With the replicated datasets (n=1000) derived from the bootstrap sample procedure, 
uncertainties around hazard ratio estimates can be measured. 
Bootstrapping results for the internal validation reflect the robustness of the 
final model (HR 95%CI percentile for LDH: 1.039 to 2.628 and HR 95%CI percentile 
for Ang-2 (log value): 1.161 to 2.263). 
 
Sensitivity analysis 
Considering the differences observed between the two cohorts (table 1), we 
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performed a sensitivity analysis to validate the robustness of our final model with a 
stratified approach in the Cox modelisation. 
With this approach similar results were obtained for the univariate analysis 
except for timing to metastases parameters, which were reported to be non-
statistically significant (Supp data table 1). The multivariate analysis confirmed that 
Ang-2 and LDH were two independent predictors for OS (HR=1.800; 95%IC: 1.081-
2.998; p=0.0239 and HR=1.548; 95%IC: 1.028-2.331; p=0.0365, respectively). 
 
Added value of the Ang-2 parameter for predicting Overall Survival 
Then, we decided to investigate the performance improvement in OS discrimination 
after the inclusion of Ang-2 measurement in a reference prognostic model.  
Currently, in our situation two main staging systems are available: Kohne and 
GERCOR scores. In our population the Kohne model cannot be calculated. However, 
GERCOR score displayed a better discriminative ability (C=0.64) than Kohne model 
(C=0.55).(24) We then used the GERCOR model as the reference score.  
Ang-2 was first identified as a factor independently associated with OS (HR=1.568 
95%CI=1.111- 2.213; p=0.0104). Then, the inclusion of the Ang-2 parameter in the 
GERCOR reference model significantly improved its discriminative ability since the 
C-statistic increased significantly from 0.61 to 0.63 (bootstrap mean difference=0.07, 
95% CI: 0.069-0.077). 
The integrated discrimination improvement was 0.03 (p=0.07). Similarly, the 
addition of Ang-2 measurement to the reference model showed a favourable trend to 
adequately reclassified patients at lower risk for death and those at higher risk, as 
reported by a continuous net reclassification improvement of 0.26 (95%CI: -0.23 to 
0.75). Indeed for patients without death at 48 months Ang-2 measurement moved 
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risk prediction in the correct (downward) direction in 11/18=61%. Conversely, 
patients with death indicate a correct, upward, change in risk assessment when using 
the Ang-2 measurement (47/91=52%). The risk reclassification analysis (IDI and NRI) 
results are greater than 0 and statistically border line reflecting a favourable tendency 
for Ang-2 parameter. 
 
Proposal for an implementation of Ang-2 monitoring in clinical practice  
After the statistical investigation and determination of the baseline Ang-2 added value 
for predicting OS among the conventional factors, we investigated the possibility to 
provide a simple implementation of Ang-2 monitoring in clinical practice. 
 
Cut-off value of Ang-2 fixed at 5 ng/mL 
Simple implementation of Ang-2 monitoring in clinical practice is first guided by the 
determination for a relevant cut-off in order to categorize patients into groups with low 
and high Ang-2 level at baseline. 
A preliminary set of experiments was done by dosing the Ang-2 value in 41 
healthy volunteers, blood donors in the Etablissement Français du Sang (EFS, 
Bourgogne Franche-Comté). These volunteers were major (more than 55 years old), 
having signed an informed consent and were randomly chosen. We hypothesized 
that this population have no active angiogenesis. Among these healthy donors, 40 
(98%) had mean values lower than 5 ng/mL. This observation was in agreement with 
the results previously published by Goede et al where levels of Ang-2 were inferior to 
5 ng/mL in the 33 healthy volunteers. 
In our study population, the median value of Ang-2 was 4.045 ng/mL for the 
109 patients included in the final analysis. Of note, similar results were observed 
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when the median value was used as a cut-off. A value of 5 ng/mL was then chosen 
considering results provided by previous publications (17, 20) regarding that 98% of 
healthy volunteers have baseline plasmatic levels of Ang-2 below 5ng/mL. In 
consequence, in order to investigate a cut-off value for clinical use, a level of 5 ng/mL 
seemed to be a relevant choice (Figure 2). 
 
Phenotypic characterisation of patients with high and low Ang-2 levels 
The determination of 5 ng/mL as a cut-off value allowed us to classify patients into 
two groups: low (<5 ng/mL) and high (>=5 ng/mL) Ang-2 level group at baseline. 
Among the 109 patients involved in the final analysis, 40 (36.7%) had levels of Ang-2 
above 5 ng/mL. The clinico-biological characteristics according to Ang-2 value are 
summarized in table 3. Increased Ang-2 level was associated with enhanced LDH 
levels (77%, p< 0.0001), metastatic sites (63% liver and other, p=0.04515), and 
synchronous metastases (92%, p< 0.0001). Patients with high Ang-2 levels exhibited 
more surgery of the primary tumor, increased leucocytes count and lymphopenia. 
As expected, we noted a significant difference for the GERCOR prognostic 
score distribution among groups of patients with low and high Ang-2 levels (42%-
38%-20% vs 7%-48%-45%; p=0.0002 for low, intermediate and high risk GERCOR 
group, respectively). 
 
Kaplan-Meier curves for OS by combining Ang-2 binary information and conventional 
score 
Considering the added value of Ang-2 measurement for OS risk stratification among 
conventional factors, previously described, we investigated the interest for a 
combination of Ang-2 simple binary information and GERCOR prognostic score in 
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clinical practice. 
In our population, 30 (59%) and 79 (63%) patients are eligible for the 
GERCOR score calculation among the 51 and 126 patients in the cohort set-1 and 2, 
respectively (Fisher-exact test p= 0.7332). In total, data were available to assess the 
GERCOR prognostic score in 109 patients. This risk model identified 32 patients at 
“low-risk”, 45 patients at “intermediate-risk”, and 32 patients at “high-risk” level. In our 
study, the median OS was 27.1 months 95%CI: 20.2-38.4 for the low-risk, 24.3 
months 95%CI: 19.3-29.5 for the intermediate-risk and 19.7 months 95%CI: 12.3-
23.8 for the high-risk group (figure 3, panel A, global p-logrank=0.02). 
According to the Ang-2 value, the median OS was significantly better in 
patients with low levels of Ang-2 than in patients with high levels of Ang-2 (median 
OS=26.2 months, 95%CI: 23.2-34.5 vs 17.8 months, 95%CI: 10.1-24.1, respectively, 
HR=2.06; 95%CI: 1.37-3.09; p<0.0001) (figure 3, panel B). 
Finally, the Ang-2 binary status was combined with the GERCOR score. In low 
and high-risk patients, the Ang-2 value only triggers a trend in better discrimination of 
prognosis, without statistical significance (p=0.27 and 0.45, respectively). However, 
in the intermediate risk GERCOR group (n=45, 41%), the consideration of Ang-2 
binary status allowed us to split the population in two subsets of patients. Indeed, 
patients with low Ang-2 level had a significant better prognosis than those with high 
Ang-2 level (26.3 95%CI: 22.2-38.2 vs 17.6 months 95%CI: 7.6-29.5 p=0.02; 
HR=2.07 95%IC=1.11-3.86) (figure 3, panel C). 
Interestingly, patients with intermediate risk and Ang-2< 5 ng/mL (n=26, 58%) 
had a similar risk profile than the GERCOR low risk patients (OS=26.3 and 27.1 
months, respectively). Similarly, those with Ang-2> 5 ng/mL (n=19, 42%) had a 
similar risk profile than the GERCOR high-risk patients (OS=17.6 and 19.7 months, 
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respectively, figure 3, panel D). 
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DISCUSSION: 
 
The present results, consistently with previous studies, confirm that Angiopoietin-2 is 
a biomarker of interest for OS prediction in non-previously treated mCRC 
patients.(17-18) The main interest of Ang-2 as a biomarker is its ability to predict OS 
when measured at diagnosis, before treatment initiation. Low levels of Ang-2 identify 
a significant population (n=69; 63%) displaying an encouraging median OS of 26.2 
months (HR=2.06; 95%CI: 1.37-3.09; p<0.0001). 
Identification of patients with a favourable prognosis at baseline might be of 
clinical interest to better individualize cancer therapies. Such prognostic biomarkers 
might enable the appropriate selection of patients eligible to intermittent 
chemotherapy or sequential therapeutic strategies dedicated to the optimization of 
patient’s quality of life and chemotherapy cost-effectiveness.(5-6, 34) 
In our cohort, the GERCOR model allows the identification of 32 (29%) 
patients of good prognosis, with a median OS of 27.1 months. When considering the 
population exhibiting both low Ang-2 level and low GERCOR risk, no difference was 
established in OS, as well as for elevation of Ang-2 level and high GERCOR risk.  
However, considering the intermediate GERCOR subgroup risk (n=45, 41% of 
patients in the present study) the binary Ang-2 status succeeded in reclassifying the 
prognostic risk into a low (n=26, 58%) and a high risk (n=19, 42%), corresponding to 
those of GERCOR model. In this case, the soluble Ang-2 value appears to be of 
particular interest since i) the intermediate subgroup represents a consequent 
number of patients, and ii) the relevance of an intermediate group in clinical practice 
is not clear leading to considerable confusion for their management. 
There are some limitations in our study. First, all patients of these cohorts 
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were treated with bevacizumab and chemotherapy, excluding the possibility to 
analyse the predictive value of Ang-2. This question was recently addressed by 
Llovet et al in the SHARP study.(16) Ang-2 was monitored in 491 hepatocellular 
carcinoma patients treated by sorafenib or placebo. Baseline plasma Ang-2 was 
correlated to OS both in sorafenib and placebo groups, ruling out a predictive value 
of Ang-2 in the context of this anti-angiogenic therapy. More recently the predictive 
impact of Ang-2 has also been assessed in pancreatic cancer. In that study, three 
seric factors have been proposed as predictive for efficacy in 328 patients treated by 
gemcitabine with bevacizumab or placebo, including Ang-2, Stomal-cell Derived 
Factor-1 (SDF1) and VEGF-D.(35) Another limitation of our study is the absence of 
PAL recording in the “cohort set-2”. Nevertheless, we did not observe any 
association between PAL and Ang-2 in the “cohort set-1” Moreover, the GERCOR 
analysis, performed on 803 mCRC patients treated by FOLFOX or FOLFIRI in the 
first-line setting demonstrated that LDH, number of metastatic sites and PS were the 
only independent prognostic factors.(24)  
From a statistical point of view, the assessment of models performance 
measures such as discrimination, calibration, and internal validation strengthen the 
present investigation. While the model developed here has good calibration, 
discrimination and robust internal validation (reproducibility), these results have to be 
replicated and confirmed in a prospectively recruited validation cohort, in order to 
ensure wider transportability and generalizability of our results. 
One scheming observation is the association between Ang-2 level and 
presence of the primary tumor. Surgery of the primary tumor was linked to a 
decreased probability to observe plasmatic Ang-2 in mCRC patients (76% Ang-2< 5 
ng/mL vs 54% Ang-2> 5 ng/mL). The prognostic value of primary tumor resection still 
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remains a matter of debates. It appears to be significantly associated with OS in our 
univariate analysis, but not in the multivariate one. Many clinical and biological 
investigations support a potential role of the presence of the primary carcinoma in 
mCRC prognosis.(36-39) Data reported in two phase III clinical trials CAIRO and 
CAIRO II, and a recent meta-analysis suggested a prognostic association of primary 
tumor removal with OS in mCRC patients.(38, 40-42) The potential association of 
primary colorectal cancer on Ang-2 production might account for its potential 
detrimental effect on prognosis. Prospective studies should monitor Ang-2 production 
before and following primary tumor resection.  
The biological basis underlying the adverse role of Ang-2 also deserves further 
investigations. There are some evidences that VEGF is early expressed during 
cancer progression (43) Ang-2 could be overexpressed in latter stages of the 
disease, as suggested by Abajo et al.(44) In line with this hypothesis, the production 
of Ang-2 within the tumor microenvironment could depend on VEGF.(44) Moreover, 
Ang-2 expression was shown to be correlated with colorectal cancer stages and 
progression.(44-45) Nevertheless the precise role of Ang-2 cancer progression need 
to be further clarified. 
 
In conclusion, the assessment of the Ang-2 value at baseline could guide 
clinicians in stratifying risk for death in first-line mCRC patients and in providing a 
basis for early and adapted therapeutic interventions. The determination of Ang-2 at 
baseline should allow death risk stratification that could also be useful in the design 
optimization for future clinical trials. 
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Table 1: Baseline Characteristics of Patients, according to the cohort set 
 
Characteristics 
Overall 
population 
(N =177) 
Cohort set-1 
(N =51) 
Cohort set-2 
(N =126) P† 
 N  N  N  
Age — years ‡   51  126   
  <= 65 177 93 (53%)  27 (53%)  66 (52%)  
  >65  84 (47%)  24 (47%)  60 (48%) p = 0.9461 
Patient male sex — no. (%)‡ 177 74 (42%) 51 28 (55%) 126 46 (37%) p = 0.0246 
Performance status OMS ‡ 167       
  0— no. (%)  91 (55%) 48 27 (56%) 119 64 (54%)  
  >0— no. (%)  76 (45%)  21 (44%)  55 (46%) p = 0.7719 
Primary Tumor site ‡ 177  51  126   
  Colon — no. (%)  120 (68%)  32 (63%)  88 (70%)  
  Rectum — no. (%)  57 (32%)  19 (37%)  38 (30%) p = 0.3602 
Metastases localisation ‡ 177  51  126   
  Liver and other  — no. (%)  98 (55%)  17 (33%)  81 (64%)  
  Liver alone — no. (%)  68 (39%)  23 (45%)  45 (36%)  
  Other alone — no. (%)  11 (6%)  11 (22%)  0 (0%) p <0.0001 
Timing of metastases  ‡ 173  48  125   
  Synchrone  — no. (%)  119 (69%)  30 (63%)  89 (71%)  
  Metachrone — no. (%)  54 (31%)  18 (37%)  36 (29%) p = 0.2688 
Surgery of the primary 
tumor  — no. (%)‡ 
175 110 (63%) 49 28 (57%) 126 82 (65%) p = 0.3293 
Leucocyte (x106/mL)* 137 8.1 ± 3.2 49 8.1 ± 3.5 88 8.2 ± 3.0 p = 0.8926 
Lymphocyte (x106/mL)* 132 1.5 ± 0.7 45 1.7 ± 0.7 87 1.4 ± 0.6 p = 0.0550 
LDH ‡ 115  33  82   
  <=350 (ULN)  56 (49%)  20 (61%)  36 (44%)  
  >350 (ULN)  59 (51%)  13 (39%)  46 (56%) p = 0.1050 
Ang-2 (ng/mL) ** 177 
4.249 
(2.683-7.153) 
51
2.793 
(2.103-4.330) 
126 
4.728 
(3.298-7.798) 
p <0.0001 
Death event ‡ 177  51 36 (71%) 126 126 (100%) p <.0001 
Median F-up time in months 
95%CI  
All patients were F-up until death 
   
57.9 
(53.1-60.3) 
 
Max time 
observed = 
64.1 
 
* Plus–minus values are means ±SD and the unpaired t-test was used for the comparison of variable among groups. 
** Median and Inter-quartile range are described and the Wilcoxon rank sum test was used for the comparison of variable 
among groups. 
† P values are for the comparison between cohort set-1 and cohort set-2 populations 
‡ Chi-square or Fisher exact tests were used for the comparison of categorical variables,. 
Abbreviations: PS, performance status ULN : Upper Limit of Normal 
Bold characters represent significative results. 
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Table 2: Univariate and multivariate analyses (*) 
 
 Number 
of 
patients 
Number 
of 
deaths 
Univariate analysis Multivariate analysis 
Multivariate 
analysis with 
bootstrap 
procedure 
 HR 95%CI P HR 95%CI P 95% percentile CI 
Age — years           
  <= 65 93 84 1 - -     
  >65 84 78 1.243 [0.912; 1.694] 0.1689     
Sex          
  Male 74 65 1       
  Female 103 97 1.310 [0.955; 1.798] 0.0941     
Performance 
status OMS        
  
  0 91 80 1       
  >0 76 73 1.274 [0.927; 1.751] 0.1355     
Primary Tumor 
site        
  
  Colon  120 113 1       
  Rectum 57 49 0.855 [0.610; 1.196] 0.3597     
Timing to 
metastasis         
  
  Metachronous  119 111 1       
  Synchronous 54 47 1.458 [1.035; 2.054] 0.0308     
Metastases 
localisation        
  
  Liver alone 68 59 1       
  Liver and 
other 98 95 1.816 [1.305; 2.527]    
  
  Other alone  11 8 0.686 [0.326; 1.442] 0.0003     
Surgery of the 
primary tumor         
  
  Yes 110 101 1       
  No 65 59 1.433 [1.035; 1.984] 0.0304     
Leucocyte 
(x106/mL)* 137 122 1.120 [1.056; 1.188] 0.0002   
  
Lymphocyte 
(x106/mL)* 132 120 0.795 [0.589; 1.073] 0.1339   
  
LDH ‡          
  <=350 (ULN) 56 49 1   1    
  >350 (ULN) 59 58 2.026 [1.373; 2.988] 0.0004 1.598 [1.040; 2.454] 0.0323 [1.039; 2.628]
Log_Ang-2 
(pg/mL) 177 162 1.911 [1.492; 2.448] <.0001 1.587 [1.138; 2.213] 0.0065 [1.161; 2.263]
 
* CI denotes confidence interval. 
Abbreviations: PS, performance status ULN : Upper Limit of Normal 
Bold characters represent significative results. 
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Table 3 Baseline characteristics of the patients involved in the multivariate analysis 
according to the Ang-2 level (n=109)  
 
  Ang-2 < 5 ng/mL 
(n=69) 
Ang-2 >=5 ng/mL 
(n=40) 
 
 n p† 
Age — years ‡     
<= 65 56 31 (45) 25 (63)  
>65 53 38 (55) 15(37) 0.11 
Sex‡     
Male 45 39 (57) 25 (63)  
Female 64 30 (43) 15 (37) 0.54 
Performance status OMS‡     
0 57 41 (59) 16 (40)   
>0 52 28(41) 24 (60) 0.07 
Primary Tumor site‡     
Colon  73 46(67) 27 (68)  
Rectum 36 23(33) 13 (32) 0.93 
Timing to metastasis ‡     
Synchronous 74 39 (57) 35 (92)  
Metachronous 32 29 (43) 3 (8) < 0.0001 
Metastases localisation‡     
Liver alone 43 28 (41) 15 (37)  
Liver and other 58 33 (48) 25 (63)  
Other alone  8 8 (12) 0 (0) 0.04515 
Surgery of the primary tumor ‡      
No 73 16 (24) 18 (46)  
Yes 34 52 (76) 21 (54) 0.0189 
Leucocyte (x106/mL)* 89 7.3713±2.3972 9.4180± 3.8269 0.0026 
Lymphocyte (x106/mL)* 85 1.6589±0.6355 1.2187±0.5816 0.0017 
LDH ‡     
<=350 (ULN) 52 43 (62) 9 (23)  
>350 (ULN) 57 26 (38) 31 (77) < 0.0001 
GERCOR score‡     
0 Low-risk 32 29 (42) 3 (7)  
1 Intermediate-risk 45 26 (38) 19 (48)  
2 High-risk 32 14 (20) 18 (45) 0.0002 
 
* Plus–minus values are means ±SD and the unpaired t-test was used for the comparison of variable among groups. 
† P values are for the comparison between cohort set 1 and cohort set 2 populations 
‡ Chi-square or Fisher exact tests were used for the comparison of categorical variables,. 
Abbreviations: PS, performance status 
Bold characters represent significative results. 
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Figure 1: Flow chart and Analysis plan of the study.  
Population selection during the study is summarized in the flow chart. 
In the left panel the population selection during the study is described.  
In the right panel the derived analysis and their synthetic results are summarized. 
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Figure 2: Distribution of Ang-2 measurement value among Healthy Volunteers 
(n=41) and mCRC patients (n=109) involved in the final analysis. 
In our study population, the median value of Ang-2 was 4.045 ng/mL for the 109 
patients included in the final analysis. In consequence, in order to investigate a cut-
off value for clinical use, a level of 5 ng/mL seemed to be a relevant choice. 
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Figure 3: Kaplan–Meier Curves for Overall Survival 
 
Panel A shows the classic approach based on the GERCOR’s score in which LDH 
and OMS are key parameters. 
Panel B shows the stratification according to the level of Ang-2. 
Panel C shows the stratification according to the level of Ang-2 in the 45 (41%) 
patients classified in intermediate risk with GERCOR’s score. 
Panel D shows that the determination of Ang-2 in the intermediate risk patients with 
GERCOR's group (n=45) reclassified these patients in two groups with similar 
profiles than low and high risk GERCOR’s groups. 
 
 
